Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $46.3 million.

  • Spyre Therapeutics' Total Non-Current Liabilities fell 1957.8% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year decrease of 1957.8%. This contributed to the annual value of $54.1 million for FY2024, which is 6905.37% up from last year.
  • Per Spyre Therapeutics' latest filing, its Total Non-Current Liabilities stood at $46.3 million for Q3 2025, which was down 1957.8% from $83.1 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Total Non-Current Liabilities ranged from a high of $83.1 million in Q2 2025 and a low of $20.8 million during Q4 2022
  • For the 5-year period, Spyre Therapeutics' Total Non-Current Liabilities averaged around $40.1 million, with its median value being $35.8 million (2021).
  • Per our database at Business Quant, Spyre Therapeutics' Total Non-Current Liabilities crashed by 6276.64% in 2024 and then skyrocketed by 27545.88% in 2025.
  • Spyre Therapeutics' Total Non-Current Liabilities (Quarter) stood at $26.0 million in 2021, then dropped by 19.75% to $20.8 million in 2022, then surged by 53.45% to $32.0 million in 2023, then soared by 69.05% to $54.1 million in 2024, then fell by 14.4% to $46.3 million in 2025.
  • Its Total Non-Current Liabilities stands at $46.3 million for Q3 2025, versus $83.1 million for Q2 2025 and $70.7 million for Q1 2025.